Enlarged Prostate (BPH): Medications, Minimally Invasive Procedures, and When Surgery Is Needed

Research-informed explainer — last updated April 12, 2026

Benign prostatic hyperplasia (BPH) — the non-cancerous enlargement of the prostate that squeezes the urethra — affects over half of men by age 60 and nearly 90% by age 85, but most cases can be managed without major surgery if treatment is started at the right time. The evidence strongly supports starting with medications for mild to moderate symptoms, reserving procedures for men who fail medical therapy or develop complications.

This article draws on research from four urologists who helped define BPH standards. Kevin McVary, MD, Director of Male Health at Loyola University Medical Center, was lead author of both the landmark MTOPS trial (cited over 2,000 times) showing combination drug therapy outperforms single agents in preventing BPH progression, and the 2011 AUA BPH guideline update. Howard Goldman, MD, Professor at Cleveland Clinic's Glickman Urological and Kidney Institute, co-authored the International Continence Society's standardized terminology for male lower urinary tract symptoms — the framework doctors use to characterize and measure symptom severity. Mark Tyson, M.D., at Mayo Clinic Arizona, published surgical and procedural outcome comparisons relevant to intervention decisions. Israel Franco, MD, Clinical Professor of Urology at Yale, contributed standardization research on lower urinary tract function.

Understanding BPH symptoms

BPH causes lower urinary tract symptoms (LUTS) that fall into two categories, as defined in the ICS terminology report co-authored by Dr. Goldman:

Obstructive (voiding) symptoms: Weak stream, straining to void, prolonged urination, incomplete bladder emptying, intermittency (stream that stops and starts), post-void dribbling.

Irritative (storage) symptoms: Urgency, frequency (urinating more than 8 times per 24 hours), nocturia (waking to urinate more than once per night), urgency incontinence.

Symptom severity is measured with the International Prostate Symptom Score (IPSS), which asks 7 questions scored 0-5. Total scores of 0-7 indicate mild symptoms, 8-19 moderate, and 20-35 severe.

When symptoms alone justify treatment (and when they do not)

The AUA BPH guideline authored by Dr. McVary establishes that watchful waiting (lifestyle modification, monitoring) is appropriate for men with mild symptoms (IPSS 0-7) and acceptable quality of life. Medication should be offered to men with moderate to severe symptoms (IPSS 8+) who wish to reduce symptom burden or prevent progression.

Absolute indications for intervention — where medication is not enough — include:

• Acute urinary retention that required catheter placement
• Recurrent urinary tract infections caused by incomplete bladder emptying
• Bladder stones secondary to obstruction
• Recurrent gross hematuria from BPH
• Renal insufficiency attributable to obstruction (bilateral hydronephrosis)

First-line medications

Alpha blockers (tamsulosin, silodosin, alfuzosin, doxazosin, terazosin)

Alpha-1 adrenergic blockers relax smooth muscle in the prostate and bladder neck, reducing outlet resistance. They improve urinary flow rates and IPSS scores within days to weeks. Effect is symptomatic — they do not shrink the prostate or reduce the risk of long-term progression to urinary retention.

Common side effects: dizziness, retrograde ejaculation (especially silodosin — up to 28%), orthostatic hypotension with doxazosin and terazosin.

5-alpha reductase inhibitors (finasteride, dutasteride)

5-ARIs block the conversion of testosterone to dihydrotestosterone (DHT), the primary driver of prostate growth. They shrink the prostate by 20-30% over 6-12 months. Unlike alpha blockers, they reduce the long-term risk of urinary retention and the need for surgery.

5-ARIs are most appropriate for men with prostate volumes greater than 30-40 grams. Side effects include decreased libido, erectile dysfunction, and ejaculatory dysfunction in approximately 5-10% of men. They also reduce PSA by about 50%, which must be accounted for in cancer screening interpretation.

Combination therapy: the MTOPS trial evidence

The landmark MTOPS trial (Medical Therapy of Prostatic Symptoms), of which Kevin McVary was a lead author, enrolled 3,047 men and randomized them to doxazosin alone, finasteride alone, combination therapy, or placebo over a mean follow-up of 4.5 years. Key findings:

• Combination therapy reduced the risk of overall clinical progression by 66% compared with placebo (p<0.001)
• Doxazosin alone reduced progression by 39%; finasteride alone by 34%
• Combination therapy reduced the risk of acute urinary retention by 79% and the need for invasive therapy by 67%
• Combination therapy produced significantly greater symptom score improvement than either agent alone

MTOPS established that combination therapy is preferred for men with larger prostates (>30g) who have both storage and voiding symptoms and wish to reduce long-term risk of progression.

PDE5 inhibitors (tadalafil 5mg daily)

Tadalafil is FDA-approved for LUTS/BPH, alone or in combination with tamsulosin. It has a modest but statistically significant effect on IPSS scores and improves coexisting erectile dysfunction — a relevant benefit since many BPH patients are middle-aged men with both conditions.

Minimally invasive surgical therapies (MISTs)

When medications fail or are poorly tolerated, several office-based or ambulatory procedures are available that do not require hospital admission:

UroLift (prostatic urethral lift): Small implants delivered cystoscopically that mechanically retract obstructing prostate lobes away from the urethra. Avoids heat-based tissue damage. Minimal ejaculatory dysfunction. Suitable for smaller prostates without a large median lobe. Clinical data shows IPSS improvement of approximately 11 points at 5 years with high preservation of sexual function.

Rezum (water vapor therapy): Steam energy delivered transurethrallyto ablate excess prostate tissue. Prostate shrinks over 3-6 months. Effective for small to moderate glands. Temporary catheterization is needed post-procedure. Ejaculatory function generally preserved.

iTind (temporary implantable nitinol device): Placed for 5 days to reshape the prostatic urethra and may improve symptoms long term. Minimal data beyond 2 years.

Surgical options when MISTs or medications fail

TURP (transurethral resection of the prostate): Still considered the gold-standard surgical treatment. A resectoscope removes obstructing prostate tissue endoscopically. IPSS improvement averages 70-75%. Risk of retrograde ejaculation is 65-90%; incontinence risk under 5%; re-treatment rate about 5-10% at 10 years. The 2014 systematic review by Dr. McVary's group confirmed that TURP remains the benchmark against which new techniques are compared.

HoLEP (holmium laser enucleation of the prostate): Laser enucleates the entire transition zone of the prostate, regardless of size. Superior to TURP for large prostates (>100g). Similar functional outcomes; requires specialized training. Retrograde ejaculation rate similar to TURP.

Aquablation (robotic hydrodissection): Image-guided robot delivers high-velocity saline to remove prostate tissue; lower rates of retrograde ejaculation than TURP (10-15%). Suitable for complex anatomy.

Simple open or robotic prostatectomy: Reserved for very large prostates (>100-150g) where endoscopic approaches are technically difficult.

Questions to ask your doctor

• What is my IPSS score, postvoid residual urine volume, and prostate size — and what does this mean for my treatment options?
• Have I been screened to rule out prostate cancer before starting treatment?
• Given my prostate size, am I a better candidate for an alpha blocker alone or combination therapy?
• Are there office-based procedures (UroLift, Rezum) I could try before TURP?
• How important is preserving ejaculatory function to me, and which procedures best protect it?
• If I have urinary retention or renal impairment, how urgently do I need an intervention?

The bottom line

BPH treatment follows a clear evidence-based ladder: lifestyle modification for mild symptoms, alpha blockers for rapid symptom relief, 5-ARIs or combination therapy for larger prostates where preventing long-term progression matters, and minimally invasive procedures or TURP when medications are insufficient. The MTOPS trial established that combination alpha blocker plus 5-ARI is the most effective medical regimen for reducing progression risk. Men who develop complications — retention, recurrent UTIs, bladder stones, or renal insufficiency — should not be managed with medications alone and need prompt urological evaluation for procedural intervention.